德适生物继续冲击「医学影像大模型第一股」：2025年前三季度营收同比增470%

Core Viewpoint - Hangzhou Deshi Biotechnology Co., Ltd. is advancing its IPO process on the Hong Kong Stock Exchange, aiming to become the first company in the field of medical imaging large models, with significant revenue growth driven by its unique market position and favorable policies [1][2]. Group 1: Company Overview - Established in 2016, Deshi Biotechnology focuses on AI in medical imaging and smart equipment, offering a diverse product portfolio including six software products, three commercial medical devices, four main reagents and consumables, and two technology licensing products [2]. - The core product, AI AutoVision®, specializes in intelligent analysis of chromosome karyotypes, having completed clinical trials and received recognition as a Class III innovative medical device from the National Medical Products Administration [2]. Group 2: Technology and Innovation - The success of AI AutoVision® is supported by the underlying technology platform iMedImage™, which enhances product functionality and cross-scenario applications, covering 19 types of medical imaging modalities and over 90% of clinical scenarios [3]. - iMedImage™ is noted as the largest medical imaging base model globally, integrating pre-trained medical imaging technology, thus overcoming limitations of disease-specific and modality-specific small models [3]. Group 3: Market Potential - The AI medical imaging market in China is projected to grow from 2.4 billion yuan in 2024 to 40.1 billion yuan by 2030, with a compound annual growth rate of 60.2% [4]. - Policy support is evident, with the National Health Commission and other departments promoting AI medical imaging applications, aiming for widespread clinical diagnostic services in hospitals by 2030 [4]. Group 4: Funding and Future Plans - Deshi Biotechnology has secured investments from various institutions and plans to use IPO proceeds primarily for the development and commercialization of AI AutoVision®, as well as for other software and medical device R&D [4].